Skip to content
The Policy VaultThe Policy Vault

Krazati (adagrasib) — Medica

Ampullary adenocarcinoma

Initial criteria

  • age ≥ 18 years
  • metastatic disease
  • KRAS G12C mutation-positive disease
  • used as subsequent therapy

Approval duration

1 year